| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
In relation to Mycobacterium tuberculosis, ciprofloxacin has a MIC50 of 0.25 μg/mL[1]. Acinetobacter species are attacked by ciprofloxacin. The MIC90s of Stenotrophomonas maltophilia (Xanthomonas) and are, respectively, 0.03 and 2 μg/ml[2]. Cadrofloxacin inhibits the growth of Neisseria species, Moraxella catarrhalis, and Haemophilus influenzae. The MIC90 value is 0.06 μg/mL or less[2]. Cadrofloxacin is effective against Enterobacteriaceae family members, with a median MIC90 of 0.06 μg/mL and a range of 0.015 to 16 μg/mL [2].
|
|---|---|
| ln Vivo |
Rats' hepatic CYP2E1 activity is increased by cadefloxacin (9 mg/kg; ig; once or twice daily for 14 days) [2].
|
| Animal Protocol |
Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rats, body weight 180-220 g[2]
Doses: 9 mg/kg Route of Administration: 1 or 2 times a day, Ig for 14 days Experimental Results: CYP2E1 mRNA expression in liver was enhanced, compared with the control group increased 1.6-fold, which was the same as the control rats. The level of CYP2E1 protein in liver microsomes was Dramatically higher than that of control rats, accounting for 190% of that of control rats. |
| References |
[1]. Biedenbach DJ, et al. Antimicrobial activity of CS-940, a new trifluorinated quinolone. Antimicrob Agents Chemother. 1995 Oct;39(10):2325-30.
[2]. Bryskier A, et al. Fluoroquinolones and tuberculosis. Expert Opin Investig Drugs. 2002 Feb;11(2):233-58. |
| Molecular Formula |
C19H20F3N3O4
|
|---|---|
| Molecular Weight |
411.3812
|
| Exact Mass |
411.141
|
| Elemental Analysis |
C, 55.47; H, 4.90; F, 13.85; N, 10.21; O, 15.56
|
| CAS # |
153808-85-6
|
| Related CAS # |
128427-55-4 (HCl);153808-85-6;
|
| PubChem CID |
189912
|
| Appearance |
Solid powder
|
| Density |
1.458g/cm3
|
| Boiling Point |
602.4ºC at 760mmHg
|
| Flash Point |
318.1ºC
|
| Vapour Pressure |
2.33E-15mmHg at 25°C
|
| Index of Refraction |
1.588
|
| LogP |
2.967
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
29
|
| Complexity |
702
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1(N2C3C(=CC(F)=C(N4CCNC(C)C4)C=3OC(F)F)C(=O)C(C(O)=O)=C2)CC1
|
| InChi Key |
QBDBUKJBJJWZMG-VIFPVBQESA-N
|
| InChi Code |
InChI=1S/C19H20F3N3O4/c1-9-7-24(5-4-23-9)15-13(20)6-11-14(17(15)29-19(21)22)25(10-2-3-10)8-12(16(11)26)18(27)28/h6,8-10,19,23H,2-5,7H2,1H3,(H,27,28)/t9-/m0/s1
|
| Chemical Name |
1-cyclopropyl-8-(difluoromethoxy)-6-fluoro-7-[(3S)-3-methylpiperazin-1-yl]-4-oxoquinoline-3-carboxylic acid
|
| Synonyms |
CS940; CS 940; CS-940
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~10 mg/mL (~24.31 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (2.43 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (2.43 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1 mg/mL (2.43 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4308 mL | 12.1542 mL | 24.3084 mL | |
| 5 mM | 0.4862 mL | 2.4308 mL | 4.8617 mL | |
| 10 mM | 0.2431 mL | 1.2154 mL | 2.4308 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
